Literature DB >> 19938810

Enantioselective total synthesis of (-)-acylfulvene and (-)-irofulven.

Dustin S Siegel1, Grazia Piizzi, Giovanni Piersanti, Mohammad Movassaghi.   

Abstract

We report our full account of the enantioselective total synthesis of (-)-acylfulvene (1) and (-)-irofulven (2), which features metathesis reactions for the rapid assembly of the molecular framework of these antitumor agents. We discuss (1) the application of an Evans Cu-catalyzed aldol addition reaction using a strained cyclopropyl ketenethioacetal, (2) an efficient enyne ring-closing metathesis cascade reaction in a challenging setting, (3) the reagent IPNBSH for a late-stage reductive allylic transposition reaction, and (4) the final RCM/dehydrogenation sequence for the formation of (-)-acylfulvene (1) and (-)-irofulven (2).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19938810      PMCID: PMC2805080          DOI: 10.1021/jo901926z

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  58 in total

1.  Modular, parallel synthesis of an illudinoid combinatorial library.

Authors:  Michael C Pirrung; Hao Liu
Journal:  Org Lett       Date:  2003-05-29       Impact factor: 6.005

2.  FUNGAL METABOLITES. THE STRUCTURES OF THE NOVEL SESQUITERPENOIDS ILLUDIN-S AND -M.

Authors:  T C MCMORRIS; M ANCHEL
Journal:  J Am Chem Soc       Date:  1965-04-05       Impact factor: 15.419

3.  Production of Illudin M and of a Fourth Crystalline Compound by Clitocybe Illudens.

Authors:  M Anchel; A Hervey; W J Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  1952-11       Impact factor: 11.205

4.  On the mechanism of toxicity of illudins: the role of glutathione.

Authors:  T C McMorris; M J Kelner; W Wang; S Moon; R Taetle
Journal:  Chem Res Toxicol       Date:  1990 Nov-Dec       Impact factor: 3.739

5.  A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.

Authors:  Werner Hilgers; Sandrine Faivre; Stéphanie Chieze; Jérôme Alexandre; François Lokiec; François Goldwasser; Eric Raymond; Carmen Kahatt; Abdelkrim Taamma; Garry Weems; John R MacDonald; Jean-Louis Misset; Esteban Cvitkovic
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

6.  Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.

Authors:  Angelo Paci; Keyvan Rezai; Alain Deroussent; Dominique De Valeriola; Micheline Re; Sophie Weill; Esteban Cvitkovic; Carmen Kahatt; Ajit Shah; Stephen Waters; Gary Weems; Gilles Vassal; François Lokiec
Journal:  Drug Metab Dispos       Date:  2006-08-08       Impact factor: 3.922

7.  Illudin S (lampterol).

Authors:  K Nakanishi; M Ohashi; M Tada; Y Yamada
Journal:  Tetrahedron       Date:  1965-05       Impact factor: 2.457

8.  Structure-activity relationship studies of illudins: analogues possessing a spiro-cyclobutane ring.

Authors:  Trevor C McMorris; Qiang Cong; Michael J Kelner
Journal:  J Org Chem       Date:  2003-12-12       Impact factor: 4.354

9.  NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven.

Authors:  Ryan A Dick; Xiang Yu; Thomas W Kensler
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

10.  Decomposition of a key intermediate in ruthenium-catalyzed olefin metathesis reactions.

Authors:  Soon Hyeok Hong; Michael W Day; Robert H Grubbs
Journal:  J Am Chem Soc       Date:  2004-06-23       Impact factor: 15.419

View more
  2 in total

1.  Asymmetric Traceless Petasis Borono-Mannich Reactions of Enals: Reductive Transposition of Allylic Diazenes.

Authors:  Yao Jiang; Regan J Thomson; Scott E Schaus
Journal:  Angew Chem Int Ed Engl       Date:  2017-12-04       Impact factor: 15.336

2.  Chiral Zn(II)-bisamidine complex as a Lewis-Brønsted combined acid catalyst: application to asymmetric Mukaiyama aldol reactions of α-ketoesters.

Authors:  Ryo Gotoh; Masahiro Yamanaka
Journal:  Molecules       Date:  2012-07-30       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.